Basmisanil


Basmisanil (INN) (developmental code names RG-1662, RO5186582) is a highly selective inverse agonist / negative allosteric modulator of GABA A receptors containing an α 5 subunit developed by Roche for the treatment of cognitive impairments associated with the syndrome Of Down. In August 2015, these are Phase II clinical trials for this indication.


Leave a Reply

Your email address will not be published. Required fields are marked *